Regenicin Participates in Regenerative Medicine Conference
NEW YORK, Nov. 17, 2010 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, recently participated in a conference celebrating the latest advancements in regenerative medicine. More than one hundred people and organizations attended the event in Walkersville, MD to reinforce their commitment to developing and delivering new cellular treatments to the patients who need them.
The conference was hosted on November 9th, by Lonza Walkersville, Inc. a subsidiary of Lonza AG, a Swiss based life science company and one of the world's leading cell therapy manufacturers. Presenters and participants emphasized the importance of nurturing public-private partnerships to support the development and delivery of new therapies for the treatment of U.S. troops and civilians.
In attendance was The U.S. Department of Defense Office of Technology Transition, the Armed Forces Institute of Regenerative Medicine, as well as members of Congress, U.S. Armed Forces personnel, scientists, firefighters, and surgeons on the frontlines of treating burns and wounds in the U.S.
Dr. Craig Eagle, who serves on Regenicin's Board of Directors, presented at the conference. "I was very moved by the solidarity and commitment of all parties, to seek out, develop and deliver new treatments for disease and catastrophic injuries," says Eagle.
Regenicin, Inc is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.
Safe Harbor Statement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Regenicin(TM), Inc.